Jie Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jie Wang has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Bin Dong
Department of Neurosurgery, First Affiliated Hospital of Dalian Medical University, Dalian, China
3 shared publications Xiumin Li
Dalian Med Univ, Dept Rehabil, Affiliated Hosp 2, Dalian 116011, Liaoning, Peoples R China
2 shared publications- Baozhi Feng
Department of Neurosurgery , First Affiliated Hospital of Dalian Medical University , Dalian , Liaoning, China , dlmedu.edu.cn
1 shared publication Bin Dong
1 shared publication- Hongtao Lv
Department of Neurosurgery, First Affiliated Hospital of Dalian Medical University, Dalian, China
1 shared publication - Huihao Ma
Department of Cardiovascular Imaging , First Affiliated Hospital of Dalian Medical University , Dalian , Liaoning, China , dlmedu.edu.cn
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in International Journal of Genomics
- Vol. 2026 (1) , 7575181
Single‐Cell Analysis Delineates Glutathione Metabolism–Related Gene Signatures in the Glioblastoma Microenvironment and Identifies GSTA4 as a Regulator of Malignant Behaviors
Background and Objective: The cellular distribution characteristics and functional mechanisms of glutathione (GSH) metabolism within the tumor microenvironment (TME) of glioblastoma multiforme (GBM) remain poorly understood. This study aims to elucidate the cellular landscape and GSH metabolic features of the GBM microenvironment and to clarify the role of GSH S‐transferase alpha 4 (GSTA4) in GBM progression. Methods: ScRNA‐seq was performed on 104,789 GBM cells to systematically identify cell subpopulations and construct cell interaction networks. The pseudotime analysis was conducted on 50 GSH metabolism–related genes. Differential expression of GSTA4 in GBM cell lines (U87 MG, LN229, and U251) and normal human astrocytes (SVG p12) was validated by quantitative PCR (qPCR) and Western blotting. Subsequently, siRNA and plasmid vectors were employed to establish cellular models with GSTA4 overexpression or knockdown. The functional impact of GSTA4 expression on cell proliferation, invasion, and migration was systematically evaluated. Finally, rescue experiments confirmed that GSTA4 modulates GBM cell function via the Wnt/β‐catenin signaling pathway. Results: ScRNA‐seq analysis identified 10 major cell types, including tumor cells, proliferating cells, immune cells, and stromal cells. Elevated GSH metabolic activity was predominantly observed in proliferating cells. The pseudotime analysis indicates that GSTA4 exhibits high expression levels in the intermediate state of tumor cells. Functional experiments confirmed significant upregulation of GSTA4 in GBM cells. Silencing GSTA4 expression suppressed cell proliferation, invasion, and migration, whereas its overexpression enhanced these malignant phenotypes. Moreover, this study is the first to demonstrate that GSTA4 promotes tumorigenicity and aggressive phenotypes in GBM cells through the Wnt/β‐catenin signaling pathway. Conclusion: This study reveals the reprogramming characteristics of GSH metabolism in the GBM microenvironment at the single‐cell level. Furthermore, functional experiments demonstrate that GSTA4 acts as an oncogenic driver in GBM. Collectively, these findings advance the mechanistic understanding of GBM and identify GSTA4 as a promising therapeutic target for precision intervention.
- 1 January 2026
- Published by Wiley in International Journal of Genomics
- Vol. 2026 (1) , 7575181
Open AccessSingle‐Cell Analysis Delineates Glutathione Metabolism–Related Gene Signatures in the Glioblastoma Microenvironment and Identifies GSTA4 as a Regulator of Malignant Behaviors
Background and Objective: The cellular distribution characteristics and functional mechanisms of glutathione (GSH) metabolism within the tumor microenvironment (TME) of glioblastoma multiforme (GBM) remain poorly understood. This study aims to elucidate the cellular landscape and GSH metabolic features of the GBM microenvironment and to clarify the role of GSH S‐transferase alpha 4 (GSTA4) in GBM progression. Methods: ScRNA‐seq was performed on 104,789 GBM cells to systematically identify cell subpopulations and construct cell interaction networks. The pseudotime analysis was conducted on 50 GSH metabolism–related genes. Differential expression of GSTA4 in GBM cell lines (U87 MG, LN229, and U251) and normal human astrocytes (SVG p12) was validated by quantitative PCR (qPCR) and Western blotting. Subsequently, siRNA and plasmid vectors were employed to establish cellular models with GSTA4 overexpression or knockdown. The functional impact of GSTA4 expression on cell proliferation, invasion, and migration was systematically evaluated. Finally, rescue experiments confirmed that GSTA4 modulates GBM cell function via the Wnt/β‐catenin signaling pathway. Results: ScRNA‐seq analysis identified 10 major cell types, including tumor cells, proliferating cells, immune cells, and stromal cells. Elevated GSH metabolic activity was predominantly observed in proliferating cells. The pseudotime analysis indicates that GSTA4 exhibits high expression levels in the intermediate state of tumor cells. Functional experiments confirmed significant upregulation of GSTA4 in GBM cells. Silencing GSTA4 expression suppressed cell proliferation, invasion, and migration, whereas its overexpression enhanced these malignant phenotypes. Moreover, this study is the first to demonstrate that GSTA4 promotes tumorigenicity and aggressive phenotypes in GBM cells through the Wnt/β‐catenin signaling pathway. Conclusion: This study reveals the reprogramming characteristics of GSH metabolism in the GBM microenvironment at the single‐cell level. Furthermore, functional experiments demonstrate that GSTA4 acts as an oncogenic driver in GBM. Collectively, these findings advance the mechanistic understanding of GBM and identify GSTA4 as a promising therapeutic target for precision intervention.
- Open Access
- 1 January 2025
- Published by Wiley in International Journal of Genomics
- Vol. 2025 (1)
A Novel Signature of Disulfidptosis‐Related lncRNAs Predicts Prognosis in Glioma: Evidence From Bioinformatic Analysis and Experiments
Glioma is the most common primary malignant brain tumor, characterized by high mortality and poor prognosis. Disulfidptosis, a recently identified form of regulated cell death, has been implicated in tumor progression; however, its role in glioma remains unclear. In this study, we developed and validated a novel prognostic signature based on disulfidptosis‐related long noncoding RNAs (DRLs) by integrating transcriptomic and clinical data from The Cancer Genome Atlas. Seven DRLs were identified to construct a risk model that effectively stratified patients into high‐ and low‐risk groups with significantly different overall survival outcomes. Functional enrichment and immune‐related analyses revealed that the high‐risk group exhibited distinct immune microenvironment features, including altered immune cell infiltration, immune checkpoint expression, and activity of immune‐related pathways, suggesting a potential link between DRLs and immune modulation. Drug sensitivity analysis identified several chemotherapeutic agents and targeted inhibitors with higher predicted efficacy in the high‐risk group, offering insights into personalized treatment strategies. In vitro experiments further demonstrated that LINC02542 knockdown significantly suppressed glioma cell proliferation, migration, and invasion. Collectively, these findings indicate that the DRL signature functions as an independent prognostic indicator and a potential biomarker for immune landscape profiling and immunotherapy response prediction in glioma. This integrative multiomics approach provides novel perspectives for precision immunotherapy and targeted therapy in glioma.
- 1 January 2025
- Published by Wiley in International Journal of Genomics
- Vol. 2025 (1)
Open AccessA Novel Signature of Disulfidptosis‐Related lncRNAs Predicts Prognosis in Glioma: Evidence From Bioinformatic Analysis and Experiments
Glioma is the most common primary malignant brain tumor, characterized by high mortality and poor prognosis. Disulfidptosis, a recently identified form of regulated cell death, has been implicated in tumor progression; however, its role in glioma remains unclear. In this study, we developed and validated a novel prognostic signature based on disulfidptosis‐related long noncoding RNAs (DRLs) by integrating transcriptomic and clinical data from The Cancer Genome Atlas. Seven DRLs were identified to construct a risk model that effectively stratified patients into high‐ and low‐risk groups with significantly different overall survival outcomes. Functional enrichment and immune‐related analyses revealed that the high‐risk group exhibited distinct immune microenvironment features, including altered immune cell infiltration, immune checkpoint expression, and activity of immune‐related pathways, suggesting a potential link between DRLs and immune modulation. Drug sensitivity analysis identified several chemotherapeutic agents and targeted inhibitors with higher predicted efficacy in the high‐risk group, offering insights into personalized treatment strategies. In vitro experiments further demonstrated that LINC02542 knockdown significantly suppressed glioma cell proliferation, migration, and invasion. Collectively, these findings indicate that the DRL signature functions as an independent prognostic indicator and a potential biomarker for immune landscape profiling and immunotherapy response prediction in glioma. This integrative multiomics approach provides novel perspectives for precision immunotherapy and targeted therapy in glioma.
- Open Access
- 12 October 2024
- Published by Elsevier in Journal of Neurorestoratology
- Vol. 12 (4)
Letter to Editor: Correspondence to "Two sides of one coin: Neurorestoratology and Neurorehabilitation"
- 12 October 2024
- Published by Elsevier in Journal of Neurorestoratology
- Vol. 12 (4)
Open AccessLetter to Editor: Correspondence to "Two sides of one coin: Neurorestoratology and Neurorehabilitation"
- Open Access
- 23 August 2024
- Published by Elsevier in Journal of Neurorestoratology
- Vol. 12 (4)
Correspondence: “Application of deep brain stimulation and transcranial magnetic stimulation in stroke neurorestoration: A review”
- 23 August 2024
- Published by Elsevier in Journal of Neurorestoratology
- Vol. 12 (4)
Open AccessCorrespondence: “Application of deep brain stimulation and transcranial magnetic stimulation in stroke neurorestoration: A review”
- Open Access
- 10 May 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (9) , 5867-5868
Letter to the Editor ‘A real-time augmented reality robot integrated with artificial intelligence for skin tumor surgery - experimental study and case series’
An abstract is unavailable. This article is available as a PDF only.
- 10 May 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (9) , 5867-5868
Open AccessLetter to the Editor ‘A real-time augmented reality robot integrated with artificial intelligence for skin tumor surgery - experimental study and case series’
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 13 February 2014
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 8 (1) , 50
A primary malignant fibrous histiocytoma of the scalp and intracranial tumor bleeding: a case report
A malignant fibrous histiocytoma occurring on the scalp near a primary operation site is extremely rare.
- 13 February 2014
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 8 (1) , 50
Open AccessA primary malignant fibrous histiocytoma of the scalp and intracranial tumor bleeding: a case report
A malignant fibrous histiocytoma occurring on the scalp near a primary operation site is extremely rare.